Latham & Watkins represented Octagon Therapeutics in the transaction. Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, has announced the initiation of a...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here